Romidepsin (FK228) is a class I HDAC inhibitor [108] and was the second FDA-approved HDAC inhibitor for the treatment of refractory CTCL and PTCL [109]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.